Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.36 |
| ▸ | FAP | Q12884 | 4/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31469723 | 0.84 | DPP4 (0.34) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL18672305 | 0.71 | — | — | |
| SCHEMBL3614888 | 0.71 | — | — | |
| SCHEMBL16375966 | 0.71 | SLC6A3 (0.35) | NOTUM | |
| SCHEMBL14160918 | 0.70 | LMNA (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL3080090 | 0.69 | — | — | |
| SCHEMBL16336309 | 0.67 | TSHR (0.56) | — | |
| SCHEMBL7752266 | 0.67 | POLB (0.41) | NOTUM | |
| SCHEMBL6480952 | 0.67 | INMT (0.33) | DPP4DPP8DPP9FAPPREP | |
| SCHEMBL29120268 | 0.67 | TOP2A (0.42) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598383-B2 | Reactive oxygen species-based prodrugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598383-B2 | Reactive oxygen species-based prodrugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150005352-A1 | REACTIVE OXYGEN SPECIES-BASED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-01 | — | — | US | disclosed |
| US-20150005352-A1 | REACTIVE OXYGEN SPECIES-BASED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005352-A1 | REACTIVE OXYGEN SPECIES-BASED PRODRUGS | ROS1, NOX4, NOX1 | DPP4 2275/4885DPP7 2121/4885DPP8 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.